HomeInsightsStock Comparison

Morepen Laboratories Ltd vs Sanofi India Ltd Stock Comparison

Morepen Laboratories Ltd vs Sanofi India Ltd Stock Comparison

Last Updated on: Apr 30, 2025

Key Highlights

  • The Latest Trading Price of Morepen Laboratories Ltd is ₹ 61.6 as of 30 Apr 09:57.
  • The p/e ratio of Morepen Laboratories Ltd changed from 12.7 to 22.4 over 5 quarters. This represents a CAGR of 57.45% The p/e ratio of Sanofi India Ltd changed from 30.8 to 0 over 7 quarters. This represents a CAGR of -100.00% .
  • The market cap of Morepen Laboratories Ltd changed from ₹ 429.13 crore to ₹ 2149 crore over 5 quarters. This represents a CAGR of 262.97% The market cap of Sanofi India Ltd changed from ₹ 18578 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% .
  • The revenue of Morepen Laboratories Ltd for the Dec '24 is ₹ 458.12 crore as compare to the Sep '24 revenue of ₹ 442.71 crore. This represent the growth of 3.48% The revenue of Sanofi India Ltd for the Dec '24 is ₹ 526.3 crore as compare to the Sep '24 revenue of ₹ 503.3 crore. This represent the growth of 4.57%.
  • The ebitda of Morepen Laboratories Ltd for the Dec '24 is ₹ 40.85 crore as compare to the Sep '24 ebitda of ₹ 49.06 crore. This represent the decline of -16.73% The ebitda of Sanofi India Ltd for the Dec '24 is ₹ 122 crore as compare to the Sep '24 ebitda of ₹ 136.5 crore. This represent the decline of -10.62%.
  • The net profit of Morepen Laboratories Ltd changed from ₹ 14.63 crore to ₹ 26.69 crore over 7 quarters. This represents a CAGR of 40.99% The net profit of Sanofi India Ltd changed from ₹ 190.4 crore to ₹ 82.2 crore over 7 quarters. This represents a CAGR of -38.12% .
  • The dividend payout of Morepen Laboratories Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 175.77 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Morepen Laboratories Ltd

  • Morepen Laboratories Limited is an India-based pharmaceutical company.
  • Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
  • The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
  • It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
  • The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

About Sanofi India Ltd

  • Sanofi India Limited, (Previously known as Aventis Pharma Limited) was incorporated in May, 1956.
  • The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
  • The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
  • The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
  • It has its own manufacturing facility at Goa.

Morepen Laboratories Ltd News Hub

News

Morepen receives CDSCO nod to conduct BE studies for Resmetirom

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drug...

Read more

29 Apr 2025 09:07

News

Morepen Laboratories launches four new products for domestic market

Morepen Laboratories announced the launch of four new products'Ticapen, UdoFix, LycoMore, ...

Read more

24 Apr 2025 16:13

News

Morepen Laboratories plans to add 1,000 medical representatives

Morepen Laboratories today announced a bold expansion plan aimed at deepening its connect ...

Read more

11 Apr 2025 09:16

News

Morepen Lab jumps on plans to expand salesforce

The move is aimed at strengthening Morepen's connect with doctors, pharmacies, patients, a...

Read more

11 Apr 2025 12:05

News

Morepen Laboratories receives China NMPA approval for Loratadine

Morepen Laboratories has received approval from the Center for Drug Evaluation (CDE) of th...

Read more

01 Apr 2025 09:08

News

Morepen Lab gains after receiving Loratadine approval for export to China

Loratadine is used to temporarily relieve the symptoms of hay fever (allergy to pollen, du...

Read more

01 Apr 2025 11:04

Sanofi India Ltd News Hub

News

Sanofi India MD Rodolfo Hrosz resigns

The board of directors accepted Hrosz's resignation during a meeting held on 9 April and e...

Read more

11 Apr 2025 11:01

News

Sanofi India to convene AGM

Sanofi India announced that the 69th Annual General Meeting(AGM) of the company will be he...

Read more

19 Mar 2025 12:01

News

Board of Sanofi India recommends final dividend

Sanofi India announced that the Board of Directors of the Company at its meeting held on 2...

Read more

28 Feb 2025 09:13

News

Board of Schaeffler India recommends Final Dividend

Schaeffler India announced that the Board of Directors of the Company at its meeting held ...

Read more

27 Feb 2025 17:28

News

Sanofi India to conduct board meeting

Sanofi India will hold a meeting of the Board of Directors of the Company on 27 February 2...

Read more

14 Feb 2025 09:41

News

Sanofi India to discuss results

Sanofi India will hold a meeting of the Board of Directors of the Company on 7 November 20...

Read more

18 Oct 2024 10:45

SWOT Analysis Of Sanofi India Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Morepen Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Sanofi India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Morepen Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Morepen Laboratories Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Morepen Laboratories Ltd or Sanofi India Ltd?

Market cap of Morepen Laboratories Ltd is 3,430 Cr while Market cap of Sanofi India Ltd is 13,904 Cr

What are the key factors driving the stock performance of Morepen Laboratories Ltd and Sanofi India Ltd?

The stock performance of Morepen Laboratories Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Morepen Laboratories Ltd and Sanofi India Ltd?

As of April 30, 2025, the Morepen Laboratories Ltd stock price is INR ₹62.61. On the other hand, Sanofi India Ltd stock price is INR ₹6037.4.

How do dividend payouts of Morepen Laboratories Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Morepen Laboratories Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions